Vimta Labs Limited — PPTs, 18-07-2025: Investor Presentation

**1. Financial Highlights:**

Vimta Labs reported strong Q1 FY26 results with Total Income of ₹99.3 Cr, up 31.4% YoY. Profit After Tax (PAT) surged 36.0% YoY to ₹18.9 Cr, while EBITDA grew 33.1% YoY to ₹35.4 Cr, maintaining a healthy 35.7% margin. Capex for the quarter stood at ₹24.1 Cr. The balance sheet shows low debt of ₹7.0 Cr against ₹15.0 Cr cash.

**2. Strategic Initiatives & Growth Drivers:**

The company is focused on capacity expansions, service innovations, and new market penetration. Key growth drivers include rising demand for safe drugs, food, and clean environment, alongside a commitment to operational excellence, talent acquisition, cutting-edge technologies, and strong corporate governance.

**3. Business Developments:**

Vimta Labs operates across four key service areas: drug discovery & development, food & agri testing, electronics & electricals testing, and environment testing & consultancy. With over 41 years of experience, it boasts 600,000+ sq ft of lab space and a team of 1,300+ professionals across 10 locations.

**4. Market Position & Competitive Advantage:**

Vimta Labs holds a #1 position in India for Pharma Analytical and Food Testing, and is a leading provider for EMI/EMC testing. The company attributes its strong market standing to unparalleled infrastructure, robust compliance, continuous innovation, deep knowledge, and customer-centric long-term partnerships.

**5. Investor Implications:**

These results and strategic focus indicate positive growth potential for Vimta Labs. Strong Q1 performance, market leadership in critical segments, and a focus on expanding capabilities in high-demand areas suggest continued business expansion and value creation.